课题基金 / 基金详情

REGULATION OF CORNEAL WOUND HEALING IN TYPE I DIABETES

REGULATION OF CORNEAL WOUND HEALING IN TYPE I DIABETES
I 型糖尿病角膜伤口愈合的调节
批准号:
6207738
负责人:
IAN S ZAGON
金额:
$3.88万
依托单位国家:
美国
项目类别:
财政年份:
1999
资助国家:
美国
项目状态:
已结题
起止时间:
1999-09-30 至 2001-09-29

项目摘要

项目成果

IAN S ZAGON的其他基金

相似基金

相关文献

中文摘要
翻译
描述:(改编自申请人的摘要)描述的三个 本提案的具体目标和实现途径是:1) 确定阿片受体相互作用对细胞内环境平衡的重要性 研究OGF/受体表达对糖尿病角膜上皮细胞再生的影响 过量OGF或用纳曲酮阻断OGF活性的影响 糖尿病大鼠角膜上皮、角膜缘和结膜的DNA合成 明确内源性阿片系统与生长有关的作用 糖尿病大鼠裸眼角膜上皮细胞的再上皮化 全身性和全身性术后检查修复的上皮愈合和完整性 纳曲酮对角膜擦伤大鼠的局部治疗 3)确定与生长有关的内源性阿片系统的影响 研究阿片类药物在角膜创伤修复中的作用 受体拮抗剂对人角膜器官损伤上皮愈合的影响 文化。
英文摘要
DESCRIPTION: (Adapted from the applicant's abstract) The three described specific aims and approach to their accomplishment in this proposal are: 1) to determine the importance of opioid-receptor interaction on homeostatic cellular renewal of the diabetic corneal epithelium by studying OGF/receptor expression and the effects of excess OGF or blockade of OGF activity with naltrexone on DNA synthesis in diabetic rat corneal epithelium limbus and conjunctiva; 2) to define the role of an endogenous opioid system related to growth in the re-epithelialization of denuded corneal epithelium in diabetic rats by examining healing and integrity of the repaired epithelium after systemic and topical treatment with naltrexone of rats subjected to corneal abrasions; and 3) to ascertain the influence of an endogenous opioid system related to growth in the repair of corneal wound healing by studying the effect of opioid receptor blockade on healing of wounded epithelium in human corneas in organ culture.
期刊论文(1)
专著(0)
科研奖励(0)
会议论文
Naltrexone, an opioid antagonist, facilitates reepithelialization of the cornea in diabetic rat.
纳曲酮是一种阿片类拮抗剂,可促进糖尿病大鼠的角膜上皮再生。
DOI: 10.2337/diabetes.51.10.3055
发表时间: 2002
期刊: Diabetes
影响因子: 7.7
作者: [Zagon,IanS, Jenkins,JoeB, Sassani,JosephW, Wylie,JamesD, Ruth,TorreB, Fry,JamieL, Lang,CMax, McLaughlin,PatriciaJ]
通讯作者: McLaughlin,PatriciaJ
OGF-OGFr Axis Modulation to Prevent Diabetic Ocular Surface Complications.
OGF-OGFr Axis Modulation to Prevent Diabetic Ocular Surface Complications.
Naltrexone as a Novel Treatment for Diabetic Keratopathy
Naltrexone as a Novel Treatment for Diabetic Keratopathy
海外基金